Biotech Startups

Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine. The company is advancing a licensing-ready production platform and preclinical therapeutic candidate (MEV-N01) targeting rheumatoid arthritis.

1 investor

DARA's Result Interpretation Module provides a digitalized workflow that replaces manual document handling processes for specialists, eliminating printing, scanning, email distribution, and courier services in healthcare result management.

1 investor

Mesintel develops a proprietary target discovery platform based on fibroblast biology to accelerate drug development in cancer, fibrosis, rare diseases, tissue regeneration, and aging-related conditions. The company uses single-cell multi-omics, genetically engineered models, and AI/ML to identify novel therapeutic targets.

1 investor

Mesosil develops nanomaterial platform technology for dental materials and other applications, focusing on host-biomaterial interactions and infection prevention. The company was founded based on over a decade of nanotechnology research from its founder's doctoral work.

1 investor

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures. The company advances agonist antibody programs and operates a RAFT target discovery platform to identify new therapeutic targets.

1 investor

Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets. It advances its own pipeline while partnering with pharmaceutical companies such as MSD and Johnson & Johnson.

1 investor

META-BIOMED manufactures biodegradable surgical sutures, dental products, and bone restoration materials for orthopedic applications, serving healthcare providers globally. The company operates as a technology-intensive medical device manufacturer with products exported to over 80 countries.

1 investor

Meta-Flux builds in silico simulation software that models disease biology — cellular state, perturbation response, and therapeutic intervention — using mechanistic models grounded in public reference atlases and proprietary multi-omic data from partner biobanks. The platform targets drug discovery in neurodegeneration (Parkinson's, Alzheimer's, ALS, MSA) and immuno-oncology (breast, lung, melanoma, colorectal) to improve target selection and patient stratification.

1 investor

MetaGen provides personalized healthcare approaches based on gut microbiome analysis using proprietary metabologenomics methods. The company develops services and products that enable individuals to optimize their health by understanding and managing their unique gut microbiome composition.

1 investor

Metabolomic Diagnostics develops diagnostic tests using mass spectrometry and biomarker analysis, with a focus on women's health and pregnancy-related diseases. The company serves clinical laboratories and healthcare professionals through analytical innovation and diagnostic assay development.

1 investor

MetaCycler BioInnovations develops microorganisms that convert renewable feedstocks like food waste into polyhydroxyalkanoates (PHA), a biodegradable plastic alternative that breaks down in marine environments while maintaining traditional plastic performance properties. The company originated from University of Waterloo research in 2022.

1 investor

metaLead develops medications for treating metal-related diseases using chelation therapy, targeting improved patient quality of life. The company aims to establish its therapies as first-line treatments for various conditions.

1 investor

MetalloBio is an antimicrobials development company creating a new class of metal-based, broad-spectrum antibacterial agents to treat drug-resistant "superbug" infections. Its lead KLS-1 series targets complicated infections while its KLS-2 series is tuned for antimicrobial coatings on medical equipment such as catheters and joint implants.

1 investor

Metanova Labs uses AI and decentralized competition powered by Bittensor to approach drug discovery and design. The company focuses on accelerating molecular discovery for pharmaceutical development.

1 investor

Metastem is developing a therapy for advanced metastatic cancers. The company is in clinical development stage.

1 investor

metasThera develops drugs targeting metastatic cancer cells by focusing on the cancer-specific plasma membrane citrate transporter pmCiC, which plays a role in cancer metabolism and adaptation.

1 investor

Metavention is developing a treatment that targets the sympathetic nervous system to disrupt overactive nerves believed to contribute to high blood pressure and other metabolic diseases. The company works on a medical intervention for hypertension and related metabolic conditions.

1 investor

Metis Pharma is an AI-driven biotech company focused on nanomaterial innovation for targeted drug delivery and discovery, developing therapies for oncology, metabolic diseases, autoimmune disorders, and neurodegenerative conditions. The company has developed three core AI platforms: AiLNP for nanoparticle design, AiRNA for mRNA sequence design, and AiTEM for small molecule formulation.

1 investor

Metis Pharmaceuticals (剂泰科技) is a biotech company using AI-driven nanomaterial innovation to develop targeted drug delivery and discovery platforms — including AiLNP for nanoparticle delivery design, AiRNA for mRNA sequence design, and AiTEM for small-molecule formulation design. Its technology enables precise LNP targeting of tissues such as liver, lung, muscle, and immune cells to create therapeutic opportunities for oncology, metabolic, autoimmune, and neurodegenerative diseases.

1 investor

Metly is an AI-native pharma intelligence platform that aggregates internal and external data to search regulatory filings, clinical databases, and partnership signals, monitor competitors, and automatically update intelligence workflows. It serves pharma and biotech teams for competitive intelligence, business development, licensing, market access, and asset diligence, pairing its platform with therapeutic-area experts.

1 investor

Metrovate designs peptide-based biostimulants for crops using computational protein design and AI models. The company develops biologics applied through irrigation or foliar spray systems for high-value crops, with products co-developed alongside existing agricultural input providers.

1 investor

The Mediterranean Food Lab (MFL) uses proprietary solid-state fermentation to turn grains, legumes, and vegetables into additive-free culinary flavor ingredients that replicate the depth of meat- and bone-based dishes. Its SHO line of concentrated stocks is sold to professional chefs and food enterprises in Europe.

1 investor

MGB Biopharma is a biopharmaceutical company focused on drug development, with expertise spanning clinical practice, medical science, and the transition from preclinical to clinical development for biologics and small molecules.

1 investor

Micellae develops drug delivery formulations designed to enhance solubility and potency across multiple dosage forms for pharmaceutical, wellness, and recreational products. The company offers O2W, a flexible platform enabling manufacturers to create products with tailored release profiles while reducing active ingredient requirements.

1 investor